Amoéba S.A. (LON:0RAE)

Market Cap	51.02M +6.1%
Revenue (ttm)	606.69K +15.6%
Net Income	-7.24M
EPS	-0.12
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1
Open	0.8620
Previous Close	0.8700
Day's Range	0.8620 - 0.8620
52-Week Range	0.7500 - 1.1920
Beta	0.22
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 17, 2026

About Amoéba

Amoéba S.A. develops biological products and services for the treatment of microbiological risk in the sectors of water, health, and plant protection in France. The company has developed technology to treat water, surfaces, and chronic wounds that uses the natural biocidal capacity of the living amoeba Willaertia magna C2c Maky; and agriculture biocontrol technology for the treatment of phytopathogenic microorganisms using the lysed. Amoéba S.A. was incorporated in 2010 and is headquartered in Chassieu, France.

• Industry: Miscellaneous Chemical Products
• Founded: 2010
• Employees: 23
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RAE

Financial Performance

In 2025, Amoéba's revenue was 695,449, an increase of 15.60% compared to the previous year's 601,600. Losses were -8.30 million, 26.0% more than in 2024.

Financial numbers in EUR